Soluble Biotech: Difference between revisions
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[Image:Soluble Therapeutics logo.png|right|125px]] | [[Image:Soluble Therapeutics logo.png|right|125px]] | ||
'''Soluble | '''Soluble Biotech''' (previously '''Soluble Therapeutics LLC''' and '''Soluble BioScience''') is an operating division of Predictive Oncology Inc. which specializes in analyzing protein formulations, and establishing improvements to their solubility characteristics as a service to the pharmaceutical research industry. The company was founded in [[2008]] as a spinoff of research performed by [[Larry DeLucas]] at [[UAB]], and was housed at the [[Innovation Depot]] in downtown [[Birmingham]]. It developed a proprietary system to conduct analyses quickly and efficiently. | ||
[[Joseph Garner]] was hired as CEO in [[2010]] to lead business development efforts. In [[2012]] the company was awarded a $1 million grant to help commercialize its technology for sale. In [[2014]] Soluble Therapeutics acquired Dilyx Biotechnologies of Seattle, Washington. In [[2016]] the company graduated from Innovation Depot. Later that same year it was acquired by CytoBiosciences of San Antonio, Texas. | [[Joseph Garner]] was hired as CEO in [[2010]] to lead business development efforts. In [[2012]] the company was awarded a $1 million grant to help commercialize its technology for sale. In [[2014]] Soluble Therapeutics acquired Dilyx Biotechnologies of Seattle, Washington. In [[2016]] the company graduated from Innovation Depot. | ||
Later that same year it was acquired by CytoBiosciences of San Antonio, Texas. That company maintained a cell development laboratory at the Innovation Depot. In September [[2018]] CytoBiosciences also acquired [[BioDtech]], another Innovation Depot company. | |||
In February [[2019]] CytoBiosciences was taken over Divine Capital Markets of New York City and rebranded as InventaBioTech Inc. In June [[2020]] the company's Soluble Therapeutics and BioDTech divisions were sold to Predictive Oncology Inc. of Eagan, Minnesota. | |||
{{stub}} | {{stub}} | ||
| Line 10: | Line 14: | ||
* Hoppe, Ian (October 2, 2014) "Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology." {{BN}} | * Hoppe, Ian (October 2, 2014) "Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology." {{BN}} | ||
* Brown, Melissa (December 21, 2016) "Birmingham biotech startup acquired by San Antonio company." {{BBJ}} | * Brown, Melissa (December 21, 2016) "Birmingham biotech startup acquired by San Antonio company." {{BBJ}} | ||
* Bailey, W. Scott (September 12, 2018) "San Antonio's CytoBioscience closing in on acquisition deal." ''San Antonio Business Journal'' | |||
* Bailey, W. Scott (February 7, 2019) "SA biotech gets interim CEO as it rebrands." ''San Antonio Business Journal'' | |||
* "Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech." (June 2, 2020) Predictive Oncology Inc. press release | |||
==External links== | ==External links== | ||
* [ | * [https://solublebiotech.com/home/ Soluble Biotech] website | ||
[[Category: | [[Category:Biotechnology]] | ||
[[Category:2008 establishments]] | [[Category:2008 establishments]] | ||
[[Category:2016 disestablishments]] | [[Category:2016 disestablishments]] | ||
[[Category:Innovation Depot]] | [[Category:Innovation Depot]] | ||
Latest revision as of 14:08, 30 August 2021
Soluble Biotech (previously Soluble Therapeutics LLC and Soluble BioScience) is an operating division of Predictive Oncology Inc. which specializes in analyzing protein formulations, and establishing improvements to their solubility characteristics as a service to the pharmaceutical research industry. The company was founded in 2008 as a spinoff of research performed by Larry DeLucas at UAB, and was housed at the Innovation Depot in downtown Birmingham. It developed a proprietary system to conduct analyses quickly and efficiently.
Joseph Garner was hired as CEO in 2010 to lead business development efforts. In 2012 the company was awarded a $1 million grant to help commercialize its technology for sale. In 2014 Soluble Therapeutics acquired Dilyx Biotechnologies of Seattle, Washington. In 2016 the company graduated from Innovation Depot.
Later that same year it was acquired by CytoBiosciences of San Antonio, Texas. That company maintained a cell development laboratory at the Innovation Depot. In September 2018 CytoBiosciences also acquired BioDtech, another Innovation Depot company.
In February 2019 CytoBiosciences was taken over Divine Capital Markets of New York City and rebranded as InventaBioTech Inc. In June 2020 the company's Soluble Therapeutics and BioDTech divisions were sold to Predictive Oncology Inc. of Eagan, Minnesota.
References
- Swant, Martin (June 17, 2012) "Birmingham biotech company wins National Institutes of Health $1 million grant." The Birmingham News
- Hoppe, Ian (July 30, 2014) "Birmingham is on the front lines of medical research: take a look at this biotech startup." The Birmingham News
- Hoppe, Ian (October 2, 2014) "Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology." The Birmingham News
- Brown, Melissa (December 21, 2016) "Birmingham biotech startup acquired by San Antonio company." Birmingham Business Journal
- Bailey, W. Scott (September 12, 2018) "San Antonio's CytoBioscience closing in on acquisition deal." San Antonio Business Journal
- Bailey, W. Scott (February 7, 2019) "SA biotech gets interim CEO as it rebrands." San Antonio Business Journal
- "Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech." (June 2, 2020) Predictive Oncology Inc. press release
External links
- Soluble Biotech website